Sarepta Therapeutics (NASDAQ:SRPT) Raised to “Outperform” at Wolfe Research

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by equities research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report issued on Thursday, MarketBeat.com reports. The brokerage currently has a $27.00 price objective on the biotechnology company’s stock. Wolfe Research’s price objective would indicate a potential upside of 42.48% from the stock’s current price.

Several other brokerages have also issued reports on SRPT. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, June 29th. Mizuho lifted their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Citigroup upped their target price on Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Finally, Wedbush lifted their price target on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Nine research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and seven have issued a Sell rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus target price of $25.09.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $18.95 on Thursday. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -19.74, a PEG ratio of 0.22 and a beta of 0.21. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $25.32. The stock’s 50 day moving average price is $17.75 and its 200 day moving average price is $19.29.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. During the same period in the previous year, the company earned ($3.42) earnings per share. Sarepta Therapeutics’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics will post 3.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new stake in Sarepta Therapeutics during the third quarter worth about $25,000. Ancora Advisors LLC grew its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Allworth Financial LP grew its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 851 shares during the period. 86.68% of the stock is owned by institutional investors.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Wolfe Research upgraded Sarepta Therapeutics to outperform and set a $27 price target, signaling meaningful upside potential. Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Outperform at Wolfe Research
• Neutral Sentiment: Piper Sandler trimmed its price target on Sarepta to $20 from $23 but kept a neutral rating, suggesting limited near-term conviction rather than a clear bearish call. Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $20.00 at Piper Sandler
• Negative Sentiment: Broad biotech-sector weakness is weighing on Sarepta and peers like Moderna and ImmunityBio, with investors pulling back after a strong 2026 rally in the group. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
• Negative Sentiment: Zacks Research downgraded Sarepta to strong sell, adding to the negative sentiment around the stock. Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.